Managed service or reagent-rental contracts bundle the capital cost of an instrument into a fixed per-test or per-procedure price across a multi-year term, eliminating customer CapEx and locking in consumables share. Instead of buying an analyzer, a lab pays through reagent purchases or a per-test fee that covers the instrument and service. Contracts typically have minimum volume commitments and multi-year terms. Pricing must follow Anti-Kickback safe harbor rules where federal payers are involved.

Why it matters

Standard in IVD, increasingly common in imaging AI and surgical capital. Revenue recognition (ASC 842 lease vs service) requires careful structuring.

Common pitfalls

•Confusing the commercial contract with regulatory obligations for device servicing and maintenance.
•Failing to establish clear responsibilities for software updates and cybersecurity patching in managed service agreements.
•Assuming that the financial arrangement absolves the legal manufacturer of post-market surveillance duties.
•Neglecting to consider the impact of service level agreements on device uptime and regulatory reporting requirements.
•Improperly classifying the service under financial accounting standards (e.g., ASC 842 if a lease rather than a service) can have audit and compliance implications.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.